| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 11/16/2022 | 14.16% | Chardan Capital | → $2.5 | Downgrades | Buy → Neutral |
| 09/09/2022 | 82.65% | Morgan Stanley | $5 → $4 | Maintains | Equal-Weight |
| 08/24/2022 | 128.31% | Morgan Stanley | $6 → $5 | Maintains | Equal-Weight |
| 08/15/2022 | 128.31% | Chardan Capital | $12 → $5 | Maintains | Buy |
| 11/02/2021 | 1794.98% | JMP Securities | $44 → $41.5 | Maintains | Market Outperform |
| 11/01/2021 | 447.95% | Chardan Capital | → $12 | Upgrades | Neutral → Buy |
| 06/23/2021 | 1635.16% | JMP Securities | $36 → $38 | Maintains | Market Outperform |
| 06/23/2021 | 1178.54% | Cantor Fitzgerald | → $28 | Initiates Coverage On | → Overweight |
| 05/03/2021 | 493.61% | Morgan Stanley | $14 → $13 | Maintains | Equal-Weight |
| 04/12/2021 | 721.92% | Jefferies | $11 → $18 | Upgrades | Hold → Buy |
| 01/19/2021 | 539.27% | Morgan Stanley | $6 → $14 | Maintains | Equal-Weight |
| 12/23/2020 | 1132.88% | JMP Securities | → $27 | Initiates Coverage On | → Outperform |
| 11/11/2020 | 173.97% | Morgan Stanley | $8 → $6 | Maintains | Equal-Weight |
| 05/21/2020 | 265.3% | Morgan Stanley | → $8 | Downgrades | Overweight → Equal-Weight |
| 05/12/2020 | 858.9% | BMO Capital | $24 → $21 | Maintains | Outperform |
| 05/12/2020 | 173.97% | Jefferies | $18 → $6 | Downgrades | Buy → Hold |
| 04/30/2019 | 721.92% | Jefferies | → $18 | Initiates Coverage On | → Buy |
| 01/29/2019 | 356.62% | Chardan Capital | → $10 | Initiates Coverage On | → Neutral |
| 10/12/2018 | 1269.86% | Morgan Stanley | $29 → $30 | Maintains | Overweight |
| 10/11/2018 | 1269.86% | Morgan Stanley | $29 → $30 | Maintains | Overweight |
| 06/04/2018 | 1224.2% | Morgan Stanley | → $29 | Initiates Coverage On | → Overweight |
| 06/04/2018 | — | Cowen & Co. | Initiates Coverage On | → Outperform | |
| 06/04/2018 | 1041.55% | JMP Securities | → $25 | Initiates Coverage On | → Outperform |
| 06/04/2018 | 1087.21% | BMO Capital | → $26 | Initiates Coverage On | → Outperform |
What is the target price for Evelo Biosciences (EVLO)?
The latest price target for Evelo Biosciences (NASDAQ: EVLO) was reported by Chardan Capital on November 16, 2022. The analyst firm set a price target for $2.50 expecting EVLO to rise to within 12 months (a possible 14.16% upside). 4 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Evelo Biosciences (EVLO)?
The latest analyst rating for Evelo Biosciences (NASDAQ: EVLO) was provided by Chardan Capital, and Evelo Biosciences downgraded their neutral rating.
When is the next analyst rating going to be posted or updated for Evelo Biosciences (EVLO)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Evelo Biosciences, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Evelo Biosciences was filed on November 16, 2022 so you should expect the next rating to be made available sometime around November 16, 2023.
Is the Analyst Rating Evelo Biosciences (EVLO) correct?
While ratings are subjective and will change, the latest Evelo Biosciences (EVLO) rating was a downgraded with a price target of $0.00 to $2.50. The current price Evelo Biosciences (EVLO) is trading at is $2.19, which is within the analyst's predicted range.